Merus has been granted a patent for novel PD-1 binding domains that exhibit enhanced binding affinity and potency compared to reference PD-1 antibodies. The patent includes claims for specific amino acid sequences and methods for treating diseases linked to immune suppression, such as cancer. GlobalData’s report on Merus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Merus, Personalized cancer vaccines was a key innovation area identified from patents. Merus's grant share as of June 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Novel anti-human pd-1 binding domains for cancer treatment
The granted patent US11993654B2 outlines a novel anti-human PD-1 binding domain characterized by specific amino acid sequences in its heavy chain variable region. The claims detail multiple configurations of the heavy chain complementarity-determining regions (CDRs), specifically HCDR1, HCDR2, and HCDR3, with sequences provided in SEQ ID NOs ranging from 22 to 48. Additionally, the patent includes claims for variations of the heavy chain variable region that maintain at least 90% sequence identity to the specified sequences. The binding domain may also incorporate a light chain variable region, with specific sequences for the light chain CDRs (LCDR1, LCDR2, and LCDR3) outlined in SEQ ID NOs 49 to 51.
Furthermore, the patent encompasses claims for binding moieties that include the anti-PD-1 binding domain, with an emphasis on monospecific binding moieties. It also describes pharmaceutical compositions that combine the anti-human PD-1 binding domain with a pharmaceutically acceptable carrier, indicating potential therapeutic applications. The detailed sequences and structural configurations provided in the claims suggest a focus on developing targeted therapies that could modulate immune responses, particularly in the context of cancer treatment.
To know more about GlobalData’s detailed insights on Merus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
